XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and Other Agreements - Zai Lab (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 24 Months Ended
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2018
Jun. 30, 2022
Dec. 31, 2021
Jun. 15, 2021
Dec. 31, 2020
Collaboration And Other Agreements [Line Items]                    
Revenues   $ 26,007 $ 30,757 $ 37,108 $ 47,638          
Common stock, par value (in dollars per share)   $ 0.01   $ 0.01     $ 0.01 $ 0.01    
Deferred revenue, current   $ 11,565   $ 11,565     $ 11,565 $ 20,646    
Deferred revenue, net of current portion   6,163   6,163     6,163 0    
2018 Zai Lab Agreement | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment           $ 25,000        
Non-refundable upfront payment, net of tax withholding           22,500        
Nonrefundable payment tax withholding           $ 2,500        
Potential development and regulatory milestone payments under agreement                   $ 140,000
Development and regulatory milestones recognized             9,000      
Revenues   400 0 5,400 0          
Millstone Revenue Recognized       5,000            
Zai Lab Agreement, Margetuximab | Zai Labs | Maximum                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)           20.00%        
Zai Lab Agreement, TRIDENT molecule | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)           10.00%        
Zai Lab Clinical Supply Agreements | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Revenues   100 500 300 1,600          
2021 Zai Lab Agreements | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment $ 25,000                  
Potential development and regulatory milestone payments under agreement                 $ 800,000  
Deferred revenue   1,800   1,800     $ 1,800 $ 16,100    
Revenues   $ 14,700 $ 14,400 $ 15,000 $ 14,400          
Opt-in fee                 $ 85,000  
Proceeds of stock sale 30,000                  
Sales of stock purchase price (in dollars per share)                 $ 31.3  
Potential commercial milestone payments under agreement                 $ 600,000  
Collaborative agreement transaction price                 $ 40,400  
Variable consideration recognized 5,000                  
2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital                    
Collaboration And Other Agreements [Line Items]                    
Premium received on stock purchase $ 10,400